Medical Affairs Director - Oncology Hematologic Malignancies

LAB Labcorp Early Development Laboratories Inc.; North Carolina; Presencial; USD 320.000 - 340.000; Jornada completa

Ventajas ofrecidas por este puesto de trabajo

Medical, Dental, Vision

401(k) and PTO

Employee stock purchase plan

Descripción de la vacante

Labcorp Oncology is seeking a Director, Medical Affairs - Oncology & Hematologic Malignancies to lead medical strategy, scientific exchange, and education across hematologic malignancies and broader oncology diagnostics.

You will collaborate with cross-functional teams to advance evidence-based approaches, support market access initiatives, and engage key stakeholders at national and international meetings. Travel up to 50% is expected.

Formación

• MD or DO degree from an accredited medical school.
• Board Certification in Hematology, Medical Oncology, or Hematology/Oncology.
• Fellowship training in Hematology, Medical Oncology, or Hematology/Oncology.
• 7+ years of combined clinical practice, academic medicine, diagnostics, biotechnology, pharmaceutical, or medical affairs experience.

Responsabilidades

• Provide medical affairs leadership and external engagement across hematologic malignancies and precision oncology.
• Develop medical education programs and communicate complex oncology diagnostics to internal and external audiences.
• Partner with cross-functional teams to support market access, evidence generation, and communications.

Conocimientos

Medical leadership

External engagement

Communication

Cross-functional collaboration

Educación

MD/DO

Board Certification in Hematology/Oncology

Fellowship in Hematology/Oncology

Herramientas

Molecular diagnostics

Genomic profiling

Biomarker testing

Descripción del empleo

Labcorp Oncology is seeking a Director, Medical Affairs - Oncology & Hematologic Malignancies to lead medical strategy, scientific exchange, and education across hematologic malignancies and broader oncology diagnostics.

You will collaborate with cross-functional teams to advance evidence-based approaches, support market access initiatives, and engage key stakeholders at national and international meetings. Travel up to 50% is expected.